Gilead reports positive Phase 2 results for oral ulcerative colitis drug

Gilead announced that its experimental oral therapy for ulcerative colitis achieved positive results in a Phase 2 trial.

The study reported that patients receiving the drug showed measurable clinical improvements, indicating potential efficacy for the inflammatory bowel disease.

Gilead called the outcome a "foundational asset", signaling that the candidate could become a central element of its IBD pipeline.